Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 30, 2021

SELL
$20.38 - $27.04 $305,883 - $405,843
-15,009 Closed
0 $0
Q1 2021

Apr 19, 2021

BUY
$22.75 - $34.05 $341,454 - $511,056
15,009 New
15,009 $366,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $155M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Henry James International Management Inc. Portfolio

Follow Henry James International Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Henry James International Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Henry James International Management Inc. with notifications on news.